[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618885":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":39,"responsibleParty":54,"collaborators":24,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":24,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":42,"whyStopped":24,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Methotrexate","EXPERIMENTAL","This group will recieve methotrexate 10-25mg once weekly for 3 months,",[13],"Drug: Methotrexate",{"label":15,"type":10,"description":16,"interventionNames":17},"Apremilast","This group will recieve apremilast 30mg BD for 3 months.",[18],"Drug: Apremilast",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Group A will recieve methotrexate 10-25mg once weekly for 3 months. Along with folic acid once daily except on day of methotrexate.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Group B will recieve tablet apremilast 30mg twice daily for 3 months.",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":32,"email":33},"Filza Ajmal, FCPS part 2","CONTACT","+923008179226","binteajmal1996@gmail.com",{"name":35,"role":31,"phone":36,"phoneExt":37,"email":38},"Ghafoor Ullah","923335939818","92333593818","dr_ghafoorullah@yahoo.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":24},"MTI-HMC Peshawar","RECRUITING","Peshawar","Khyber Pukhtunkhwa","25000","Pakistan","PK",{"type":49,"coordinates":50},"Point",[51,52],71.57849,34.008,{"lat":52,"lon":51},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Syeda Sana Zaman","Training medical officer","100618885","early-phase-1-to-check-comparison-of-apremilast-and-methotrexate-efficacy-in-patients-with-moderate-to-severe-plaque-psoriasis-presented-to-tertiary-care-hospital-100618885",false,"NCT07337434","To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital","Comparison of Efficacy of Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\nPatients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.\n\nExclusion Criteria:\n\nPregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs",true,"ALL","18 Years","60 Years",{"count":70,"type":71},106,"ESTIMATED","INTERVENTIONAL",[74],"EARLY_PHASE1","This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.",[77],"Chronic Plaque Psoriasis","2026-01-07",{"date":80,"type":81},"2026-01-13","ACTUAL",{"date":83,"type":71},"2025-12-25",{"date":85,"type":71},"2026-06-25",{"name":56,"class":6},1]